InterMune PT Raised to $74.00 at Robert W. Baird (ITMN)
Robert W. Baird hoisted their target price on shares of InterMune (NASDAQ:ITMN) from $50.00 to $74.00 in a research note issued on Monday. Robert W. Baird’s price objective points to a potential upside of 37.55% from the stock’s previous close.
ITMN has been the subject of a number of other recent research reports. Analysts at Wells Fargo & Co. downgraded shares of InterMune from an “outperform” rating to a “market perform” rating in a research note on Thursday. They noted that the move was a valuation call. Separately, analysts at Goldman Sachs downgraded shares of InterMune from a “buy” rating to a “neutral” rating in a research note on Thursday, August 14th. They now have a $49.00 price target on the stock, down previously from $52.06. They noted that the move was a valuation call. Finally, analysts at William Blair raised their price target on shares of InterMune from $48.00 to $55.00 in a research note on Friday, August 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $50.08.
Shares of InterMune (NASDAQ:ITMN) opened at 53.80 on Monday. InterMune has a 1-year low of $10.95 and a 1-year high of $55.24. The stock has a 50-day moving average of $45.86 and a 200-day moving average of $36.13. The company’s market cap is $5.809 billion.
InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.72) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the prior year, the company posted ($0.77) earnings per share. The company’s quarterly revenue was up 141.2% on a year-over-year basis. Analysts expect that InterMune will post $-2.75 EPS for the current fiscal year.
In other InterMune news, EVP Paul D. Arata unloaded 7,500 shares of the stock on the open market in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $50.00, for a total value of $375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Receive News & Ratings for InterMune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterMune Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.